Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4391 Comments
1753 Likes
1
{用户名称}
{用户等级}
2 hours ago
{协议答案}
👍 203
Reply
2
{用户名称}
{用户等级}
5 hours ago
{协议答案}
👍 272
Reply
3
{用户名称}
{用户等级}
1 day ago
{协议答案}
👍 119
Reply
4
{用户名称}
{用户等级}
1 day ago
{协议答案}
👍 173
Reply
5
{用户名称}
{用户等级}
2 days ago
{协议答案}
👍 253
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.